PMID: 1212662Dec 1, 1975Paper

A colon tumor model for anticancer agent evaluation

Cancer
D P Griswold, T H Corbett

Abstract

Colon tumors of mice were induced with 1, 2-dimethylhydrazine, N-nitroso-N-methylurethane, methylnitrosourea, and 4-methyl-N'-nitro-N-nitrosoguanidine. Of 82 transplantation attempts, four were successful, and the four tumors have been maintained as distinct tumor lines by subcutaneous transplantation. The tumors graded from II, adenocarcinoma, to IV, undifferentiated carcinoma. Volume-doubling times varied over a three-fold range, and metastatic potential ranged from 5 to about 100%. The tumors responded to treatment with some of the same agents found to be active in man. These included cyclophosphamide, 5-fluorouracil, and certain nitrosoureas. Preliminary evidence suggests that these tumor lines may be useful as experimental models.

References


❮ Previous
Next ❯

Citations

Jan 1, 1991·Virchows Archiv. A, Pathological Anatomy and Histopathology·M S MartinA Hammann
Jan 3, 2006·International Journal of Cancer. Journal International Du Cancer·Carole BourquinStefan Endres
Mar 29, 2007·Proceedings of the National Academy of Sciences of the United States of America·Yusuke MimuraTim Elliott
Jan 1, 1991·Cancer Immunology, Immunotherapy : CII·I Nakajima, T M Chu
Nov 28, 2002·International Journal of Cancer. Journal International Du Cancer·Stephan R SchefferTim F Greten
Sep 24, 2005·The Journal of Nutrition·Vin TangprichaMichael F Holick
Oct 23, 2008·Cancer Immunology, Immunotherapy : CII·Panagiotis KaragiannisSophia N Karagiannis
Aug 25, 2010·The Journal of Immunology : Official Journal of the American Association of Immunologists·Daisuke MuraokaHiroyoshi Nishikawa
May 8, 2014·Cancer Chemotherapy and Pharmacology·Ying Yi ChenBruce C Baguley
Oct 1, 1983·Clinical & Experimental Metastasis·F A Zoetmulder, A Zwaveling
Jan 18, 2003·International Journal of Cancer. Journal International Du Cancer·Nicola K GreenLawrence S Young
Feb 20, 2016·American Journal of Physiology. Gastrointestinal and Liver Physiology·Perparim LimaniPierre-Alain Clavien
Oct 25, 2000·The Journal of Immunology : Official Journal of the American Association of Immunologists·J S Dela CruzM L Penichet
Mar 6, 2003·The Journal of Clinical Investigation·Li YangRichard M Breyer
Apr 12, 2017·The Journal of Immunology : Official Journal of the American Association of Immunologists·Serena ZilioPaolo Serafini
Jun 22, 2001·The Journal of Immunology : Official Journal of the American Association of Immunologists·D GolgherT Elliott
Aug 24, 2019·Cancer Immunology Research·Charles S TannenbaumC Marcela Diaz-Montero
Feb 10, 2012·Cancer Research·Takuro NoguchiHiroyoshi Nishikawa
May 13, 2010·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Jun MitsuiHiroshi Shiku
Jan 1, 1978·Biochemical Pharmacology·B ArdalanP S Schein

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.